Table 2 Laboratory and treatment characteristics
|  | All patients n = 32 (%) | Thrombosis n = 9 (%) | Non-trombotic n = 23 (%) | P value |
|---|---|---|---|---|
 Prolonged aPTT | 30 (94%) | 9 (100%) | 21 (91%) | 0.36 |
 Value in seconds (NV = 33 s) | 77 (27-124 s) | 97 (41-124 s) | 69 (27–120) | 0.033* |
 Lupus anticoagulant (dRVVT) | 32 (100%) | 9 (100%) | 23 (100%) |  |
 Value (NV =  < 1.2) | 2.07 | 2.13 | 2.05 | 0.71 |
 Anticardiolipin antibodies | 29 (91%) | 8 (88%) | 21 (91%) |  |
 IgG | 20 (63%) | 6 (66%) | 14 (61%) | 0.76 |
 Value (NV < 40) | 191 GPL | 188 GPL | 192 GPL | 0.86 |
 IgM | 19 (59%) | 4 (44%) | 15 (65%) | 0.28 |
 Value (NV < 40) | 153 MPL | 154 MPL | 153 MPL | 0.50 |
 Antibody profile | ||||
 LAC | 2 (6%) | 1 (11%) | 1 (4%) | 0.47 |
 LAC + ACL IgG | 10 (31%) | 4 (44%) | 6 (26%) | 0.31 |
 LAC + ACL IgM | 8 (25%) | 0 | 8 (35%) | 0.041* |
 LAC + ACL IgG + IgM | 9 (28%) | 2 (22%) | 7 (30%) | 0.64 |
 LAC + ACL IgM + B2GPI | 2 (6%) | 2 (22%) | 0 |  |
 LAC + ACL IgG + B2GPI | 1 (3%) | 0 | 1 (4%) |  |
Treatment | ||||
 Anticoagulation | 9 (28%) | 9 (100%) | 0 |  |
 Antiplatelet | 23 (72%) | 0 | 23 (100%) |  |
 Steroid | 30 (94%) | 8 (88%) | 22 (96%) |  |
 Immunosuppressant | 30 (94%) | 8 (88%) | 22 (96%) |  |
 Cyclophosphamide | 8 (25%) | 6 (66%) | 2 (9%) |  |
 Mycophenolate | 18 (56%) | 1 (11%) | 17 (74%) |  |
 Azathioprine | 4 (13%) | 1 (11%) | 3 (13%) |  |
 Rituximab | 4 (13%) | 2 (22%) | 2 (9%) |  |